ScreenPoint Medical
Summary active Updated Apr 20, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
ScreenPoint Medical is a Nijmegen, Netherlands-based medical technology company that develops Transpara, an AI-powered breast cancer detection platform used with mammography 12. Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, the company says Transpara is deployed in 30+ countries and has processed over 12 million mammograms to date 1. The company has received prior Series C backing from Insight Partners and a development partnership with Siemens Healthineers 13.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2021 | Series C | $28M | Insight Partners | — 3 |
| 2026-04-17 | Follow-on | $14M (+ $2M research grants) | Insight Partners | Siemens Healthineers 1 |
What Investors Say
No independently sourced investor quotes found.
What Founders Say
No independently sourced founder quotes found.
Sources
-
Insight Partners, “ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care,” April 17, 2026, accessed April 20, 2026. https://www.insightpartners.com/ideas/screenpoint-medical-secures-16m-to-lead-the-next-phase-of-ai-in-breast-cancer-care/↩↩↩↩
-
ScreenPoint Medical, “About Us,” accessed April 20, 2026. https://screenpoint-medical.com/about-us/↩
-
PR Newswire, “ScreenPoint Raises $28M in Series C Funding Led by Global ScaleUp Investor Insight Partners,” accessed April 20, 2026. https://www.prnewswire.com/news-releases/screenpoint-raises-28m-in-series-c-funding-led-by-global-scaleup-investor-insight-partners-301342220.html↩↩